The CRASH 3 TRIAL
The CRASH 3 study is testing whether giving patients an anti-fibrinolytic (a drug which reduces bleeding) after injury can improve outcomes. A previous study showed that the this drug, tranexamic acid, reduced death and disability if given to patients who had experienced any severe trauma (not just head injury).
Further information can be found in the information sheet below:
The CRASH 3 study is testing whether giving patients an anti-fibrinolytic (a drug which reduces bleeding) after injury can improve outcomes. A previous study showed that the this drug, tranexamic acid, reduced death and disability if given to patients who had experienced any severe trauma (not just head injury).
Further information can be found in the information sheet below: